Highlights From ECCO 13-The European Cancer Conference Paris, France October 30 to November 3, 2005.
D000284:Administration, Oral; D018943:Anthracyclines / Q000008:administration & dosage; D000911:Antibodies, Monoclonal / Q000008:administration & dosage; D061067:Antibodies, Monoclonal, Humanized; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D001859:Bone Neoplasms / Q000188:drug therapy / Q000473:pathology / Q000556:secondary; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000473:pathology / Q000628:therapy; D016190:Carboplatin / Q000627:therapeutic use; D017321:Clinical Trials, Phase I as Topic; D017322:Clinical Trials, Phase II as Topic; D004164:Diphosphonates / Q000008:administration & dosage; D000077143:Docetaxel; D005060:Europe; D005260:Female; D006801:Humans; D000077557:Ibandronic Acid; D000077341:Lapatinib; D011799:Quinazolines / Q000008:administration & dosage; D043823:Taxoids / Q000008:administration & dosage; D000068878:Trastuzumab
D018943:Anthracyclines; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D004164:Diphosphonates; D011799:Quinazolines; D043823:Taxoids; D000077341:Lapatinib; D000077143:Docetaxel; D016190:Carboplatin; D000068878:Trastuzumab; D000077557:Ibandronic Acid